Yuan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan Lin has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Huping Wu
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine
17 shared publications Shunrong Luo
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine
11 shared publicationsXianwen Xiao
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, People’s Republic of China
10 shared publicationsXie Fang
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, People’s Republic of China
10 shared publicationsZhiwen Xie
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, People’s Republic of China
10 shared publicationsHanqiao Li
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China
5 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1928830
Clinical features and management of medication-induced persistent corneal epithelial defects due to topical ophthalmic medications
Objective: To investigate the impact of subacute preservative-containing eye drop usage on the ocular surface and to observe the clinical progression and management of medication-induced persistent corneal epithelial defects (MI-PCED). Methods: This retrospective study evaluated 60 cases (60 eyes) diagnosed with MI-PCED from January 2020 to January 2024. Data on the type, frequency, and duration of topical medication usage were collected. A multidisciplinary pharmacovigilance assessment evaluated causality, severity, and preventability of the adverse events. Upon diagnosis, the offending medications were discontinued and replaced with low-toxicity, preservative-free alternatives. For advanced epithelial decompensation with stromal involvement (Grades III and IV), bandage contact lenses (BCL) and amniotic membrane transplantation (AMT) were integrated into an exploratory step-wise management approach to promote epithelial wound healing. Treatment efficacy was evaluated using slit-lamp examination and in vivo confocal microscopy (IVCM). Results: The clinical manifestation of MI-PCED initiated with epithelial roughness and dry eye symptoms, ultimately progressing to persistent epithelial defects and corneal ulcers. The severity of epithelial decompensation correlated significantly with the number of concurrent medications ( P < 0.05), administration frequency ( P < 0.001), and medication duration ( P < 0.05). Pharmacovigilance evaluation classified 80.0% of cases as “Probable” adverse drug reactions, with 58.3% graded as moderate (Grade 2) and 41.7% as severe (Grade 3). Following 7–30 days of targeted regenerative therapy, the cure rates were 88.57% for Grade I, 90.91% for Grade II, 77.78% for Grade III, and 80.00% for Grade IV. The overall cure rate was 86.67%. Conclusions: The severity of MI-PCED is heavily dependent on the type, subacute duration, and frequency of topical ophthalmic drug use. Management requires a flexible, step-wise strategy focused on restoring ocular surface homeostasis. This includes withdrawing toxic agents, preserving tear film stability with preservative-free tears, and strategically utilizing BCL and AMT to provide mechanical protection and biological support for severe epithelial decompensation.
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1928830
Open AccessClinical features and management of medication-induced persistent corneal epithelial defects due to topical ophthalmic medications
Objective: To investigate the impact of subacute preservative-containing eye drop usage on the ocular surface and to observe the clinical progression and management of medication-induced persistent corneal epithelial defects (MI-PCED). Methods: This retrospective study evaluated 60 cases (60 eyes) diagnosed with MI-PCED from January 2020 to January 2024. Data on the type, frequency, and duration of topical medication usage were collected. A multidisciplinary pharmacovigilance assessment evaluated causality, severity, and preventability of the adverse events. Upon diagnosis, the offending medications were discontinued and replaced with low-toxicity, preservative-free alternatives. For advanced epithelial decompensation with stromal involvement (Grades III and IV), bandage contact lenses (BCL) and amniotic membrane transplantation (AMT) were integrated into an exploratory step-wise management approach to promote epithelial wound healing. Treatment efficacy was evaluated using slit-lamp examination and in vivo confocal microscopy (IVCM). Results: The clinical manifestation of MI-PCED initiated with epithelial roughness and dry eye symptoms, ultimately progressing to persistent epithelial defects and corneal ulcers. The severity of epithelial decompensation correlated significantly with the number of concurrent medications ( P < 0.05), administration frequency ( P < 0.001), and medication duration ( P < 0.05). Pharmacovigilance evaluation classified 80.0% of cases as “Probable” adverse drug reactions, with 58.3% graded as moderate (Grade 2) and 41.7% as severe (Grade 3). Following 7–30 days of targeted regenerative therapy, the cure rates were 88.57% for Grade I, 90.91% for Grade II, 77.78% for Grade III, and 80.00% for Grade IV. The overall cure rate was 86.67%. Conclusions: The severity of MI-PCED is heavily dependent on the type, subacute duration, and frequency of topical ophthalmic drug use. Management requires a flexible, step-wise strategy focused on restoring ocular surface homeostasis. This includes withdrawing toxic agents, preserving tear film stability with preservative-free tears, and strategically utilizing BCL and AMT to provide mechanical protection and biological support for severe epithelial decompensation.
- Open Access
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1822984
Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy
Purpose: To evaluate the rates of chalazion recurrence following intralesional triamcinolone acetonide (TA), intense pulsed light (IPL), or combined TA + IPL therapy and to validate an AI-enhanced risk stratification strategy. Methods: This prospective, observational study enrolled 366 patients. To eliminate immortal time bias and circular reasoning, LASSO-Cox regression with 10-fold cross-validation was employed to identify purely baseline predictors: age, Demodex infection, chronicity, and meibomian gland dysfunction (MGD). These baseline predictors were integrated into a clinical Cox proportional hazards model and a survival-based XGBoost model, which were subsequently merged into a hybrid framework. Performance was assessed via time-dependent area under the curve (AUC), net reclassification improvement (NRI), Kaplan–Meier analysis, and decision curve analysis (DCA). Results: The 3-month complete resolution rate was significantly higher in the combined TA + IPL group (95.2%) compared to the TA-only (90.8%) and IPL-only (79.4%) groups ( p < 0.001). During follow-up, 60 recurrence events (16.4%) occurred. Recurrence rates differed significantly (χ 2 = 31.73, p < 0.001) as follows: IPL group (38.2%), TA group (15.4%), and TA + IPL group (8.3%). Multivariate Cox analysis revealed that demodex infection, age, chronicity, and MGD were independent risk factors for chalazion recurrence. The hybrid model achieved an AUC of 0.822, outperforming the clinical (0.745) and XGBoost (0.821) ( p < 0.05) models. AI integration significantly refined the risk estimates (NRI = 0.365, p = < 0.001). In the high-risk subgroup, recurrence rates reached 83.3–91.7% with monotherapy, whereas combined TA + IPL therapy significantly reduced the recurrence rate to 60.0%. DCA confirmed that the hybrid model consistently yielded the greatest net clinical benefit. Conclusion: A hybrid AI-clinical model significantly improved the prediction of chalazion recurrence. Combined TA + IPL therapy demonstrated superior efficacy, particularly for high-risk patients. This framework provides a robust decision-support tool for precision management and the systematic reduction of chalazion recurrence.
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1822984
Open AccessPrecision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy
Purpose: To evaluate the rates of chalazion recurrence following intralesional triamcinolone acetonide (TA), intense pulsed light (IPL), or combined TA + IPL therapy and to validate an AI-enhanced risk stratification strategy. Methods: This prospective, observational study enrolled 366 patients. To eliminate immortal time bias and circular reasoning, LASSO-Cox regression with 10-fold cross-validation was employed to identify purely baseline predictors: age, Demodex infection, chronicity, and meibomian gland dysfunction (MGD). These baseline predictors were integrated into a clinical Cox proportional hazards model and a survival-based XGBoost model, which were subsequently merged into a hybrid framework. Performance was assessed via time-dependent area under the curve (AUC), net reclassification improvement (NRI), Kaplan–Meier analysis, and decision curve analysis (DCA). Results: The 3-month complete resolution rate was significantly higher in the combined TA + IPL group (95.2%) compared to the TA-only (90.8%) and IPL-only (79.4%) groups ( p < 0.001). During follow-up, 60 recurrence events (16.4%) occurred. Recurrence rates differed significantly (χ 2 = 31.73, p < 0.001) as follows: IPL group (38.2%), TA group (15.4%), and TA + IPL group (8.3%). Multivariate Cox analysis revealed that demodex infection, age, chronicity, and MGD were independent risk factors for chalazion recurrence. The hybrid model achieved an AUC of 0.822, outperforming the clinical (0.745) and XGBoost (0.821) ( p < 0.05) models. AI integration significantly refined the risk estimates (NRI = 0.365, p = < 0.001). In the high-risk subgroup, recurrence rates reached 83.3–91.7% with monotherapy, whereas combined TA + IPL therapy significantly reduced the recurrence rate to 60.0%. DCA confirmed that the hybrid model consistently yielded the greatest net clinical benefit. Conclusion: A hybrid AI-clinical model significantly improved the prediction of chalazion recurrence. Combined TA + IPL therapy demonstrated superior efficacy, particularly for high-risk patients. This framework provides a robust decision-support tool for precision management and the systematic reduction of chalazion recurrence.
- Open Access
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1665131
Perioperative nursing outcomes and management strategies in cold plasma ablation for superficial corneal disorders
Objective: To evaluate the clinical outcomes and perioperative nursing outcomes of low-temperature plasma ablation (LTPA) for the treatment of superficial corneal diseases. Methods: This retrospective study analyzed 38 patients who underwent LTPA between June 2022 and January 2024. Patients were grouped by etiology into refractive/structural ( n = 30) and infectious ( n = 8) categories. Clinical outcomes, epithelial healing time, complications, pain scores, and digital slit-lamp image-based healing assessments were observed and compared between the two groups. Pain intensity was longitudinally monitored using visual analog scale (VAS) scores and analyzed via two-way repeated measures ANOVA. Perioperative nursing strategies and patient-reported satisfaction were also evaluated. Results: The study population consisted of 38 patients (including 16 males and 22 females), with a mean age of 51.97 ± 2.36 years (range: 22–87 years). Patients in the infectious group exhibited significantly longer epithelial healing times compared to those in the noninfectious group ( p = 0.040). Recurrence within 3 months was significantly more frequent in the infectious group (25.0%, n = 2/8 vs. 0%, n = 0/30; p = 0.005) and was associated with lower nursing satisfaction scores ( p < 0.001). Two-way repeated measures ANOVA revealed that VAS pain scores were consistently higher in the infectious group across all time points ( F = 20.33, p < 0.001), although both groups demonstrated a significant downward trend over time ( F = 241.10, p < 0.001). Quantitative analysis based on digital slit-lamp imaging facilitated the clinical observation delayed epithelial healing in 5 patients (13.2%), thereby facilitating early clinical intervention. No severe postoperative complications were reported. Conclusion: LTPA appears to be a feasible and well-tolerated approach for treating superficial corneal disorders, associated with preliminary outcomes being observed across both infectious and noninfectious etiologies. These findings suggest that perioperative nursing protocols and digital image-based monitoring may support objective healing tracking and enhance patient care, although these observational results require prospective validation.
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1665131
Open AccessPerioperative nursing outcomes and management strategies in cold plasma ablation for superficial corneal disorders
Objective: To evaluate the clinical outcomes and perioperative nursing outcomes of low-temperature plasma ablation (LTPA) for the treatment of superficial corneal diseases. Methods: This retrospective study analyzed 38 patients who underwent LTPA between June 2022 and January 2024. Patients were grouped by etiology into refractive/structural ( n = 30) and infectious ( n = 8) categories. Clinical outcomes, epithelial healing time, complications, pain scores, and digital slit-lamp image-based healing assessments were observed and compared between the two groups. Pain intensity was longitudinally monitored using visual analog scale (VAS) scores and analyzed via two-way repeated measures ANOVA. Perioperative nursing strategies and patient-reported satisfaction were also evaluated. Results: The study population consisted of 38 patients (including 16 males and 22 females), with a mean age of 51.97 ± 2.36 years (range: 22–87 years). Patients in the infectious group exhibited significantly longer epithelial healing times compared to those in the noninfectious group ( p = 0.040). Recurrence within 3 months was significantly more frequent in the infectious group (25.0%, n = 2/8 vs. 0%, n = 0/30; p = 0.005) and was associated with lower nursing satisfaction scores ( p < 0.001). Two-way repeated measures ANOVA revealed that VAS pain scores were consistently higher in the infectious group across all time points ( F = 20.33, p < 0.001), although both groups demonstrated a significant downward trend over time ( F = 241.10, p < 0.001). Quantitative analysis based on digital slit-lamp imaging facilitated the clinical observation delayed epithelial healing in 5 patients (13.2%), thereby facilitating early clinical intervention. No severe postoperative complications were reported. Conclusion: LTPA appears to be a feasible and well-tolerated approach for treating superficial corneal disorders, associated with preliminary outcomes being observed across both infectious and noninfectious etiologies. These findings suggest that perioperative nursing protocols and digital image-based monitoring may support objective healing tracking and enhance patient care, although these observational results require prospective validation.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Long-Term Clinical Outcomes of nDSAEK and Machine Learning-Based Prediction of Graft Survival in Corneal Endothelial Decompensation
Purpose: To evaluate long-term outcomes of non-Descemet stripping automated endothelial keratoplasty (nDSAEK) in low-vision patients with corneal endothelial decompensation (CED), and to develop a machine-learning framework for predicting graft failure. Methods: This retrospective study included 114 eyes (Fuchs’ and non-Fuchs’ etiologies) treated with nDSAEK. Best-corrected visual acuity (BCVA), endothelial cell density (ECD), and complications were assessed over a long-term follow-up. Linear mixed-effects models (LMM) analyzed ECD kinetics. An XGBoost model using 10 clinical features was constructed to predict graft failure, interpreted via SHapley Additive exPlanations (SHAP) analysis. Results were compared against established endothelial keratoplasty benchmarks. Results: The median follow-up was 41.50 months (IQR: 25.65– 55.75 months). Mean BCVA improved significantly from 1.80 logMAR baseline to 1.20 logMAR at 6 months, remaining stable thereafter. At 3 years, mean ECD was 1724 ± 279 cells/mm2.,Subgroup stratification demonstrating a 3-year cumulative ECD loss of 37.9% in the Fuchs’ group compared to a significantly higher long-term depletion rate of 45.3% in the non-Fuchs’ group. LMM analysis showed that femtosecond laser-assisted nDSAEK (FS-nDSAEK) significantly improved long-term ECD maintenance over manual dissection. The predictive framework yielded longitudinal risk-discrimination capability, demonstrating a time-dependent area under the ROC curve (AUC) of 0.917 (95% CI: 0.819– 1.000) at 12 months, 0.920 (95% CI: 0.823– 1.000) at 24 months, and 0.880 (95% CI: 0.765– 0.995) at 36 months, driven by 15 confirmed graft failure events within the 114-eye cohort. SHAP analysis identified FS assistance and preoperative ECD as key protective factors. Compared to literature benchmarks, nDSAEK demonstrated visual and anatomical stability demonstrated visual and anatomical trends that align with historical DSAEK cohorts. Conclusion: nDSAEK offers stable long-term visual and anatomical outcomes for CED. The integration of AI frameworks offers an exploratory framework for individualized prognostic screening, though further external validation is required before direct clinical integration.
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Open AccessLong-Term Clinical Outcomes of nDSAEK and Machine Learning-Based Prediction of Graft Survival in Corneal Endothelial Decompensation
Purpose: To evaluate long-term outcomes of non-Descemet stripping automated endothelial keratoplasty (nDSAEK) in low-vision patients with corneal endothelial decompensation (CED), and to develop a machine-learning framework for predicting graft failure. Methods: This retrospective study included 114 eyes (Fuchs’ and non-Fuchs’ etiologies) treated with nDSAEK. Best-corrected visual acuity (BCVA), endothelial cell density (ECD), and complications were assessed over a long-term follow-up. Linear mixed-effects models (LMM) analyzed ECD kinetics. An XGBoost model using 10 clinical features was constructed to predict graft failure, interpreted via SHapley Additive exPlanations (SHAP) analysis. Results were compared against established endothelial keratoplasty benchmarks. Results: The median follow-up was 41.50 months (IQR: 25.65– 55.75 months). Mean BCVA improved significantly from 1.80 logMAR baseline to 1.20 logMAR at 6 months, remaining stable thereafter. At 3 years, mean ECD was 1724 ± 279 cells/mm2.,Subgroup stratification demonstrating a 3-year cumulative ECD loss of 37.9% in the Fuchs’ group compared to a significantly higher long-term depletion rate of 45.3% in the non-Fuchs’ group. LMM analysis showed that femtosecond laser-assisted nDSAEK (FS-nDSAEK) significantly improved long-term ECD maintenance over manual dissection. The predictive framework yielded longitudinal risk-discrimination capability, demonstrating a time-dependent area under the ROC curve (AUC) of 0.917 (95% CI: 0.819– 1.000) at 12 months, 0.920 (95% CI: 0.823– 1.000) at 24 months, and 0.880 (95% CI: 0.765– 0.995) at 36 months, driven by 15 confirmed graft failure events within the 114-eye cohort. SHAP analysis identified FS assistance and preoperative ECD as key protective factors. Compared to literature benchmarks, nDSAEK demonstrated visual and anatomical stability demonstrated visual and anatomical trends that align with historical DSAEK cohorts. Conclusion: nDSAEK offers stable long-term visual and anatomical outcomes for CED. The integration of AI frameworks offers an exploratory framework for individualized prognostic screening, though further external validation is required before direct clinical integration.
- Open Access
- 15 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1696949
Imaging-based assessment of corneal graft rejection after penetrating keratoplasty: insights from confocal microscopy and anterior chamber analysis
Objective: This study aimed to explore the distribution of rejection and visual changes after optical and therapeutic penetrating keratoplasty (PKP) in Southeastern China. Methods: This retrospective study included 104 patients who underwent either optical or therapeutic PKP between December 2014 and April 2022 at the Xiamen Eye Center. The collected data included demographic characteristics, primary disease, visual acuity, in vivo confocal microscopy (IVCM) findings, and postoperative outcomes. Endothelial inflammation was assessed using IVCM, and anterior chamber paracentesis was performed on patients with recurrent rejection (>2 hospitalizations) for viral and cytokine analyses. Results: Of 104 eyes (68 men and 36 women; mean age 51.9 ± 12.9 years), 42 received optical PKP and 62 received therapeutic PKP. The mean host bed size was 7.81 ± 0.75 mm, and the graft size was 8.28 ± 0.75 mm. During follow-up, four patients developed secondary glaucoma and one relapsed. A total of 12 patients (2 optical, 10 therapeutic) required repeat PKP and were successfully managed. A larger graft size (>7.8 mm) and therapeutic PKP were identified as significant risk factors for graft rejection, whereas conjunctival congestion, infiltration depth, and femtosecond-assisted PKP were not significantly associated with rejection. Among the 40 cases with recurrent rejection, aqueous fluid analysis revealed viral infection in 20% (3 VZV, 10 HSV, and 7 CMV). Elevated levels of inflammatory cytokines were found in 32 cases, and they responded positively to steroid treatment. However, three cases showed a poor response to the treatment. Conclusion: PKP effectively addresses both optical and therapeutic indications; however, larger grafts and therapeutic PKP increase the risk of rejection. Imaging with IVCM and anterior chamber analysis provides valuable diagnostic and prognostic information, supporting individualized management of graft rejection.
- 15 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1696949
Open AccessImaging-based assessment of corneal graft rejection after penetrating keratoplasty: insights from confocal microscopy and anterior chamber analysis
Objective: This study aimed to explore the distribution of rejection and visual changes after optical and therapeutic penetrating keratoplasty (PKP) in Southeastern China. Methods: This retrospective study included 104 patients who underwent either optical or therapeutic PKP between December 2014 and April 2022 at the Xiamen Eye Center. The collected data included demographic characteristics, primary disease, visual acuity, in vivo confocal microscopy (IVCM) findings, and postoperative outcomes. Endothelial inflammation was assessed using IVCM, and anterior chamber paracentesis was performed on patients with recurrent rejection (>2 hospitalizations) for viral and cytokine analyses. Results: Of 104 eyes (68 men and 36 women; mean age 51.9 ± 12.9 years), 42 received optical PKP and 62 received therapeutic PKP. The mean host bed size was 7.81 ± 0.75 mm, and the graft size was 8.28 ± 0.75 mm. During follow-up, four patients developed secondary glaucoma and one relapsed. A total of 12 patients (2 optical, 10 therapeutic) required repeat PKP and were successfully managed. A larger graft size (>7.8 mm) and therapeutic PKP were identified as significant risk factors for graft rejection, whereas conjunctival congestion, infiltration depth, and femtosecond-assisted PKP were not significantly associated with rejection. Among the 40 cases with recurrent rejection, aqueous fluid analysis revealed viral infection in 20% (3 VZV, 10 HSV, and 7 CMV). Elevated levels of inflammatory cytokines were found in 32 cases, and they responded positively to steroid treatment. However, three cases showed a poor response to the treatment. Conclusion: PKP effectively addresses both optical and therapeutic indications; however, larger grafts and therapeutic PKP increase the risk of rejection. Imaging with IVCM and anterior chamber analysis provides valuable diagnostic and prognostic information, supporting individualized management of graft rejection.
- Open Access
- 25 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1618279
Establishment of a nomogram model to predict malignant risk in patients with ocular surface squamous neoplasia and ocular surface squamous epithelial tumors
Objective: To develop and internally validate a nomogram to predict the probability that a clinically suspected ocular surface squamous epithelial tumor is histopathologically malignant. Methods: This retrospective study included 92 patients with ocular surface squamous epithelial tumors who underwent surgical excision and histopathologic confirmation between 2015 and 2020. Lesions were classified as benign (squamous papilloma) or ocular surface squamous neoplasia (OSSN) according to the latest AJCC criteria. Clinical and pathologic parameters were analyzed using univariate and multivariate logistic regression to identify independent predictors of malignancy. These predictors were incorporated into a nomogram model. Model performance was assessed by calibration and receiver operating characteristic (ROC) curve analysis with internal validation using 1,000 bootstrap resamples. Results: Among the 92 cases, 50 (54.3%) were squamous papilloma, 24 (26.0%) were conjunctival intraepithelial neoplasia (CIN), and 15 (16.3%) were squamous cell carcinoma (SCC). After multiple factor logistic regression analysis, we selected preoperative prediction Models 1 (sex + age + corneal invasion + tumor diameter) and 2 (papillary hyperplasia + cytoplasmic changes + degree of differentiation). We established nomogram models for Models 1, 2, and 3 (Model 1+ Model 2). The results showed that all models had a good fit, which reflected a higher diagnostic value. All models could reliably discriminate malignant from benign lesions. The model predicts histopathologic malignancy (CIN/SCC) at the time of excision. Conclusion: The nomogram model based on clinicopathologic parameters provides a reliable tool for differentiating benign from OSSN. This model may assist clinicians in preoperative risk assessment, guide biopsy or excision decisions, and improve diagnostic accuracy in ocular surface tumor management.
- 25 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1618279
Open AccessEstablishment of a nomogram model to predict malignant risk in patients with ocular surface squamous neoplasia and ocular surface squamous epithelial tumors
Objective: To develop and internally validate a nomogram to predict the probability that a clinically suspected ocular surface squamous epithelial tumor is histopathologically malignant. Methods: This retrospective study included 92 patients with ocular surface squamous epithelial tumors who underwent surgical excision and histopathologic confirmation between 2015 and 2020. Lesions were classified as benign (squamous papilloma) or ocular surface squamous neoplasia (OSSN) according to the latest AJCC criteria. Clinical and pathologic parameters were analyzed using univariate and multivariate logistic regression to identify independent predictors of malignancy. These predictors were incorporated into a nomogram model. Model performance was assessed by calibration and receiver operating characteristic (ROC) curve analysis with internal validation using 1,000 bootstrap resamples. Results: Among the 92 cases, 50 (54.3%) were squamous papilloma, 24 (26.0%) were conjunctival intraepithelial neoplasia (CIN), and 15 (16.3%) were squamous cell carcinoma (SCC). After multiple factor logistic regression analysis, we selected preoperative prediction Models 1 (sex + age + corneal invasion + tumor diameter) and 2 (papillary hyperplasia + cytoplasmic changes + degree of differentiation). We established nomogram models for Models 1, 2, and 3 (Model 1+ Model 2). The results showed that all models had a good fit, which reflected a higher diagnostic value. All models could reliably discriminate malignant from benign lesions. The model predicts histopathologic malignancy (CIN/SCC) at the time of excision. Conclusion: The nomogram model based on clinicopathologic parameters provides a reliable tool for differentiating benign from OSSN. This model may assist clinicians in preoperative risk assessment, guide biopsy or excision decisions, and improve diagnostic accuracy in ocular surface tumor management.
- 21 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-12
cGAS-STING pathway-mediated inflammatory response and its role in corneal fibrosis mechanisms
- 21 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-12
cGAS-STING pathway-mediated inflammatory response and its role in corneal fibrosis mechanisms
- 8 October 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 263 (12) , 3555-3562
Timing of intravitreal foldable capsular vitreous body implantation after silicone oil tamponade
Purpose To evaluate the timing of intravitreal of foldable capsular vitreous body (FCVB) implantation following silicone oil tamponade in patients with severe ocular trauma. Methods This retrospective study included two groups of patients with severe ocular trauma who were selected from a single unit. Those in Group A underwent direct FCVB implantation without prior silicone oil tamponade, whereas those in Group B underwent temporary silicone oil tamponade before delayed FCVB implantation. Surgical outcomes and complications, including anterior chamber hemorrhage, anterior chamber shallowness, elevated intraocular pressure (IOP), and ocular pain, were observed and compared between the two groups over a one-year follow-up period to determine the optimal implantation timing. Results A total of 52 patients (52 eyes) were enrolled between January 2019 and January 2024, with 12 patients in Group A and 40 in Group B. The retinal reattachment rate in each group was 75% and 91%, respectively. Among the 15 patients who experienced anterior segment-related complications, 11 were in Group A, and 4 were in Group B. The results revealed that Group A demonstrated a higher mean follow-up IOP (27.8 mmHg) than did Group B (10.9 mmHg), and some patients required intervention for ocular hypertension. Kaplan‒Meier analysis indicated that silicone oil tamponade for ≤ 0.3 months increased the risk of anterior complications compared with that for > 0.3 months (P = 0.0176). Ultimately, fewer complications were observed in Group B than in Group A. Very short tamponade durations may not allow adequate ocular stabilization prior to FCVB implantation, contributing to increased risks of inflammation and elevated IOP. Based on clinical observations and survival analysis, the optimal timing for FCVB implantation appears to be between 2 and 3 months after initial silicone oil tamponade. Conclusion Following severe ocular trauma, a two-stage surgical approach—initial silicone oil tamponade followed by FCVB implantation after 2–3 months—yields the best treatment outcomes with minimal complications. These findings provide important guidance for clinicians in selecting the appropriate timing for FCVB surgery.
- 8 October 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 263 (12) , 3555-3562
Timing of intravitreal foldable capsular vitreous body implantation after silicone oil tamponade
Purpose To evaluate the timing of intravitreal of foldable capsular vitreous body (FCVB) implantation following silicone oil tamponade in patients with severe ocular trauma. Methods This retrospective study included two groups of patients with severe ocular trauma who were selected from a single unit. Those in Group A underwent direct FCVB implantation without prior silicone oil tamponade, whereas those in Group B underwent temporary silicone oil tamponade before delayed FCVB implantation. Surgical outcomes and complications, including anterior chamber hemorrhage, anterior chamber shallowness, elevated intraocular pressure (IOP), and ocular pain, were observed and compared between the two groups over a one-year follow-up period to determine the optimal implantation timing. Results A total of 52 patients (52 eyes) were enrolled between January 2019 and January 2024, with 12 patients in Group A and 40 in Group B. The retinal reattachment rate in each group was 75% and 91%, respectively. Among the 15 patients who experienced anterior segment-related complications, 11 were in Group A, and 4 were in Group B. The results revealed that Group A demonstrated a higher mean follow-up IOP (27.8 mmHg) than did Group B (10.9 mmHg), and some patients required intervention for ocular hypertension. Kaplan‒Meier analysis indicated that silicone oil tamponade for ≤ 0.3 months increased the risk of anterior complications compared with that for > 0.3 months (P = 0.0176). Ultimately, fewer complications were observed in Group B than in Group A. Very short tamponade durations may not allow adequate ocular stabilization prior to FCVB implantation, contributing to increased risks of inflammation and elevated IOP. Based on clinical observations and survival analysis, the optimal timing for FCVB implantation appears to be between 2 and 3 months after initial silicone oil tamponade. Conclusion Following severe ocular trauma, a two-stage surgical approach—initial silicone oil tamponade followed by FCVB implantation after 2–3 months—yields the best treatment outcomes with minimal complications. These findings provide important guidance for clinicians in selecting the appropriate timing for FCVB surgery.
- Open Access
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1614699
Case Report: IVCM of corneal chlorpromazine toxicity drug deposits
To investigate corneal deposits in a patient undergoing long-term chlorpromazine therapy using in vivo confocal microscopy with the HRT II Rostock Corneal Module. We reported a 45-year-old woman with a 7-year history of chlorpromazine therapy presented with bilateral photophobia and a 4-year history of gradual-onset blurred vision. Slit-lamp examination revealed yellowish deposits in the corneal endothelium and Descemet’s membrane. In vivo confocal microscopy identified irregular hyper-reflective deposits in all corneal layers. The epithelial and superficial stromal deposits had well-defined edges, while the posterior stromal, Descemet’s membrane, and endothelial deposits appeared as hollow granules and streaks. This study is the first to use in vivo confocal microscopy to identify crystalline deposits in the corneal stroma and endothelium caused by high-dose chlorpromazine. These findings offer new insights into drug metabolism on the ocular surface and provide a basis for future research.
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1614699
Open AccessCase Report: IVCM of corneal chlorpromazine toxicity drug deposits
To investigate corneal deposits in a patient undergoing long-term chlorpromazine therapy using in vivo confocal microscopy with the HRT II Rostock Corneal Module. We reported a 45-year-old woman with a 7-year history of chlorpromazine therapy presented with bilateral photophobia and a 4-year history of gradual-onset blurred vision. Slit-lamp examination revealed yellowish deposits in the corneal endothelium and Descemet’s membrane. In vivo confocal microscopy identified irregular hyper-reflective deposits in all corneal layers. The epithelial and superficial stromal deposits had well-defined edges, while the posterior stromal, Descemet’s membrane, and endothelial deposits appeared as hollow granules and streaks. This study is the first to use in vivo confocal microscopy to identify crystalline deposits in the corneal stroma and endothelium caused by high-dose chlorpromazine. These findings offer new insights into drug metabolism on the ocular surface and provide a basis for future research.
- Open Access
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1577656
Tear IgE point-of-care testing for differentiating type I and type IV allergic conjunctivitis
Objective: This study aimed to evaluate the diagnostic utility of point-of-care tear immunoglobulin E (IgE) testing in distinguishing between type I and type IV allergic conjunctivitis (AC), and to explore tailored treatment strategies.Methods: A total of 254 patients with perennial AC at Xiamen Eye Center were enrolled. Clinical data, including age, sex, symptoms, and signs, were collected. Tear total IgE was measured using the i-ImmunDx™ platform. Univariate and multivariate logistic regression analyses, along with ROC curve analysis, were used to assess the discriminative value of tear IgE and clinical parameters for AC subtypes.Results: The mean patient age was 14.11 ± 12.46 years; 182 were male. Mean conjunctivitis score was 4.09 ± 1.51, and mean tear IgE was 7.73 ± 16.76 IU/mL. Tear IgE levels negatively correlated with age (p < 0.05), and positively with conjunctival secretion, papillary hyperplasia, and conjunctivitis scores (p < 0.05). Univariate analysis showed age, tear IgE, and papillae were significantly associated with type IV AC. Multivariate analysis identified tear IgE, conjunctival papillae, and conjunctivitis score as independent predictors. ROC analysis showed an AUC of 0.896 for tear IgE (cut-off = 5.57 IU/mL; sensitivity 89.00%, specificity 77.78%). A combined model (IgE + papillae + score) improved AUC to 0.912, with sensitivity of 81.50% and specificity of 88.89%.Conclusion: Tear IgE effectively differentiates AC subtypes and correlates with disease severity. Patients with low IgE levels, indicative of type IV hypersensitivity, benefit from individualized anti-inflammatory therapies, supporting its role in personalized management.
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1577656
Open AccessTear IgE point-of-care testing for differentiating type I and type IV allergic conjunctivitis
Objective: This study aimed to evaluate the diagnostic utility of point-of-care tear immunoglobulin E (IgE) testing in distinguishing between type I and type IV allergic conjunctivitis (AC), and to explore tailored treatment strategies.Methods: A total of 254 patients with perennial AC at Xiamen Eye Center were enrolled. Clinical data, including age, sex, symptoms, and signs, were collected. Tear total IgE was measured using the i-ImmunDx™ platform. Univariate and multivariate logistic regression analyses, along with ROC curve analysis, were used to assess the discriminative value of tear IgE and clinical parameters for AC subtypes.Results: The mean patient age was 14.11 ± 12.46 years; 182 were male. Mean conjunctivitis score was 4.09 ± 1.51, and mean tear IgE was 7.73 ± 16.76 IU/mL. Tear IgE levels negatively correlated with age (p < 0.05), and positively with conjunctival secretion, papillary hyperplasia, and conjunctivitis scores (p < 0.05). Univariate analysis showed age, tear IgE, and papillae were significantly associated with type IV AC. Multivariate analysis identified tear IgE, conjunctival papillae, and conjunctivitis score as independent predictors. ROC analysis showed an AUC of 0.896 for tear IgE (cut-off = 5.57 IU/mL; sensitivity 89.00%, specificity 77.78%). A combined model (IgE + papillae + score) improved AUC to 0.912, with sensitivity of 81.50% and specificity of 88.89%.Conclusion: Tear IgE effectively differentiates AC subtypes and correlates with disease severity. Patients with low IgE levels, indicative of type IV hypersensitivity, benefit from individualized anti-inflammatory therapies, supporting its role in personalized management.